Research graph
References from Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis. Local targets link to admitted publications; unresolved targets remain external evidence.
Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation
10.1016/j.bbmt.2015.10.018 · 2016 · External reference
Patient-reported outcomes and health status associated with chronic graft-versus-host disease
10.3324/haematol.2018.192930 · 2018 · External reference
Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
10.1182/blood-2010-11-319509 · External reference
Disability related to chronic graft-versus-host disease
10.1016/j.bbmt.2019.10.019 · 2020 · External reference
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria
10.1182/blood-2011-03-344390 · 2011 · External reference
Peripheral-blood stem cells versus bone marrow from unrelated donors
10.1056/nejmoa1203517 · 2012 · External reference
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
10.1182/blood-2014-04-567164 · 2014 · External reference
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
2000 · External reference
Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
1998 · External reference
Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study
10.1200/jco.20.00150 · 2020 · External reference
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
10.1016/s1470-2045(09)70225-6 · 2009 · External reference
Antilymphocyte globulin for prevention of chronic graft-versus-host disease
10.1056/nejmoa1506002 · 2016 · External reference
Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation
10.1200/jco.2017.75.8177 · 2017 · External reference
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
10.1016/s2352-3026(19)30220-0 · 2020 · External reference
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303
10.1016/j.bbmt.2011.02.002 · 2011 · External reference
Naive T-cell depletion to prevent chronic graft-versus-host disease
10.1200/jco.21.01755 · 2022 · External reference
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
10.1182/blood-2013-04-495895 · 2013 · External reference
Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD
10.1200/jco.20.01086 · 2021 · External reference
Chronic graft-versus-host disease: unresolved complication or ancient history?
10.1182/blood.2023022735 · 2024 · External reference
Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study
10.1200/jco.22.00509 · 2023 · External reference
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
10.1182/blood.v72.2.546.546 · 1988 · External reference
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
10.1053/bbmt.2001.v7.pm11400948 · 2001 · External reference
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
10.1182/blood-2009-02-202937 · 2009 · External reference
Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study
10.1016/j.bbmt.2011.05.016 · 2012 · External reference
A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801
10.3324/haematol.2018.195123 · 2018 · External reference
Failure-free survival after initial systemic treatment of chronic graft-versus-host disease
10.1182/blood-2014-03-563544 · 2014 · External reference
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study
10.1182/blood.2021012021 · 2021 · External reference
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
10.1182/blood-2017-07-793786 · 2017 · External reference
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
10.1056/nejmoa2033122 · 2021 · External reference
Axatilimab in recurrent or refractory chronic graft-versus-host disease
10.1056/nejmoa2401537 · 2024 · External reference
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
10.1016/s2352-3026(18)30221-7 · 2019 · External reference
Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis
10.1056/nejmoa2215943 · 2023 · External reference
National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide
10.1200/jco.20.03502 · 2021 · External reference
Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies
10.1200/jco.21.02293 · 2022 · External reference
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults
10.1182/bloodadvances.2020001648 · 2020 · External reference
Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors
10.1016/j.bbmt.2015.03.003 · 2015 · External reference
Prospective randomized study comparing myeloablative unrelated umbilical cord blood transplantation versus HLA-haploidentical related stem cell transplantation for adults with hematologic malignancies
10.1016/j.bbmt.2019.10.014 · 2020 · External reference
Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide
10.1038/s41409-018-0279-1 · 2019 · External reference
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
10.1182/bloodadvances.2022007264 · 2022 · External reference
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial
10.1182/blood.2020007535 · 2021 · External reference
Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis
2022 · External reference
Differences in graft-versus-host disease characteristics between haploidentical transplantation using post-transplantation cyclophosphamide and matched unrelated donor transplantation using calcineurin inhibitors
10.1016/j.bbmt.2020.07.035 · 2020 · External reference
Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation
10.3324/haematol.2018.202754 · 2019 · External reference
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
10.1182/blood-2016-09-737825 · 2017 · External reference
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation
10.1038/s41409-023-02178-y · 2024 · External reference
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2020 highly morbid forms report
2021 · External reference
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study
10.1038/leu.2012.292 · 2013 · External reference
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis
10.1182/blood-2010-12-323824 · 2011 · External reference
Increased infections and delayed CD4(+) T cell but faster B cell immune reconstitution after post-transplantation cyclophosphamide compared to conventional GVHD prophylaxis in allogeneic transplantation
2021 · External reference
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
10.1101/2025.02.25.25322901 · External reference
